Skip to main content

Studies evaluate medications, biomarkers linked to GCA risk

Findings from two studies published in Rheumatology suggest that angiotensin receptor blocker use may be associated with an increased risk for developing giant cell arteritis, and that interferon-γ may warrant further investigation as a risk biomarker.


Novel nonhormonal agent shows promise for hot flashes, night sweats in patients with breast cancer

The oral nonhormonal agent Q-122 appears to be an efficacious and well tolerated option for the control of vasomotor symptoms in women with breast cancer receiving adjuvant endocrine therapy, suggest phase 2 trial data.

Headlines from across medwireNews

29-11-2022 | Diabetes | News | Article

Call to rethink CGM advice for older adults

Analysis of participants in the ORACL trial leads researchers to suggest that nonfrail older adults with type 1 diabetes are better off following time in range guidance aimed at younger people.

29-11-2022 | Rheumatology | News | Article

The metabolic syndrome may influence the risk for gout

The metabolic syndrome may be a modifiable risk factor for incident gout, suggest findings from a nationwide study of more than 1.29 million men.

28-11-2022 | Rheumatology | News | Article

Treatment goals in late-onset RA should match those for younger patients

People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.

28-11-2022 | Oncology | News | Article

Cancer screening uptake fails to return to prepandemic rates

The rates of population-based screening and diagnosis of breast, cervical, and colorectal cancer in the USA in 2021 remained below those reported before the COVID-19 pandemic, researchers caution in JAMA Oncology.

25-11-2022 | Oncology | News | Article

GIM2 defines ‘optimal’ high-risk early breast cancer adjuvant chemotherapy

End-of-study findings from the GIM2 trial indicate that adjuvant anthracyclines plus taxane chemotherapy for high-risk early breast cancer should be given in a dose-dense regimen and should not include fluorouracil.

24-11-2022 | Diabetes | News | Article

STANDby confirms diabetes remission with weight loss in South Asian population

Following a very-low-calorie total diet replacement plan can lead to type 2 diabetes remission in South Asian individuals, shows the STANDby trial.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.